Brief: Alteogen receives Europe patent
27/07/2017 04:13
July 27 (Reuters) - Alteogen Inc 196170.KQ :
* Says it received Europe patent on July 27, for new alpha-1
antitrypsin variant, method for producing the same and use
thereof
Source text in Korean: https://goo.gl/KmGT1H
Further company coverage: 196170.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'